Miralax Safety in G6PD Deficiency

Medication Safety in G6PD Deficiency

• The American College of Physicians and other medical societies agree that only seven medications are definitively contraindicated in G6PD deficiency, including Dapsone, Methylthioninium chloride (methylene blue), Primaquine, Rasburicase, which can cause hemolysis in patients with this condition 1, 2
• The severity of G6PD deficiency varies based on genetic variant and ethnic background, with the Mediterranean variant (Gdmed) typically causing more severe reactions than the African variant (GdA-), according to the Clinical Infectious Diseases guidelines 2, 3
• Screening for G6PD deficiency is recommended before starting therapy with oxidant drugs in patients with predisposing racial or ethnic backgrounds, such as those of Mediterranean, African, Indian, or Southeast Asian descent, as suggested by the Clinical Infectious Diseases guidelines 2, 3
• When starting any new medication in G6PD-deficient patients, monitoring for signs of hemolysis, such as jaundice, dark urine, fatigue, and pallor, is essential, as recommended by the Praxis Medical Insights guidelines 1